Rocky Mountain Voice

Tag: Pharmaceutical Industry

Prescription Drug Prices Post Sharpest Decline in More Than 60 Years
The Washington Post, Approved, National

Prescription Drug Prices Post Sharpest Decline in More Than 60 Years

By Steve Thompson, Federica Cocco and Christopher Rowland | The Washington Post While overall medical costs continued to rise, prescription drug prices fell by 3.1 percent in the year ending in July, the steepest annual decline since 1963. Prescription drug prices recorded the biggest year-over-year drop in more than 60 years in July, a startling reduction experts chalked up to an array of factors, including more generics and discount GLP-1 weight-loss drugs. While overall costs for medical services continued to rise, prices for medicinal drugs fell 2.7 percent over the 12 months ending in July, the largest annual drop on record, according to Bureau of Labor Statistics data released Wednesday. Prescription drugs, part of the medicinal drug category, fell by 3.1 perce...
Who Funds the Experts? Pharma Ties Emerge in Vaccine Schedule Debate
Just The News, Approved, National

Who Funds the Experts? Pharma Ties Emerge in Vaccine Schedule Debate

By Ashe Short | Just the News The groups that most Americans treat as neutral medical authorities on what to put in their kids' bloodstreams — the AMA and the AAP — both draw millions in revenue from the companies that manufacture the vaccines they are promoting. Shortly after President Donald Trump signed an executive order reducing the number of vaccines required for young children, the American Medical Association (AMA) issued a press release claiming Trump’s order puts children’s health at risk. “Vaccines are among the most thoroughly studied, effective tools we have to protect children from serious vaccine-preventable diseases,” AMA President Willie Underwood, III, said in the statement. “Decisions about how and when vaccines are used should be driven by ri...
The High Cost of Ignorance: Why Special Interests Are Fighting Prescription Drug Transparency in Colorado
Rocky Mountain Voice, Commentary, State, Top Stories

The High Cost of Ignorance: Why Special Interests Are Fighting Prescription Drug Transparency in Colorado

By Rep. Ken DeGraaf | Guest Commentary, Rocky Mountain Voice Editor’s update: House Bill 26-1056 will be heard in the House Health & Human Services Committee on Tuesday, February 17, 2026, upon adjournment in HCR 0112. The committee is scheduled between 10 a.m. and 2 p.m. Readers may listen live here: https://sg001-harmony.sliq.net/00327/Harmony/en/PowerBrowser/PowerBrowserV2/20260217/-1/18053#handoutFile_  “It is difficult to get a man to understand something when his salary depends upon his not understanding it.” — Upton Sinclair It's easy to be wrong when it makes you money.  If the average savings from using a Pharmacy Stewardship Program (PSP) are $1,500 per member per year, and Colorado has around 2 million workers covered by employer health plans, th...
Hundreds lose jobs after global pharmaceutical company closes two Colorado facilities
Fox31, Approved, State

Hundreds lose jobs after global pharmaceutical company closes two Colorado facilities

By Heather Willard | FOX31 Denver DENVER (KDVR) — A global contract development and manufacturing organization with headquarters in Seattle has announced the closure of its Boulder and Longmont locations, resulting in hundreds of laid-off workers in Colorado. AGC Biologics filed a WARN Notice with the state of Colorado on Sept. 16 about the closure of its Boulder and Longmont facilities, as well as the impact on employees who support those facilities from afar. On its website, the company says that it provides pharmaceutical development and manufacturing services for protein-based biologics, cell and gene therapies and messenger RNA. It boasts eight locations across the world, including in Japan, Denmark, Italy and Germany, but will drop to six after the two Colorado loc...
RFK Jr. targeted by Pharma’s $2 million lobbying blitz, memo shows
National File, Approved, National

RFK Jr. targeted by Pharma’s $2 million lobbying blitz, memo shows

By Ethan Fowler | National File A resurfaced leaked memo from the Biotechnology Innovation Organization (BIO), first revealed by Brownstone Institute, April 2025, details a $2 million campaign to lobby Congress for Robert F. Kennedy Jr.’s removal as HHS Secretary, highlighting Big Pharma’s ongoing desperation amid his MAHA reforms. As Kennedy’s regulatory push intensifies, this old plot—now recirculated by Malone—exposes the industry’s fear of accountability, blending fear-mongering and surrogate influence in a bid to preserve profits over public health. Why it matters: This memo underscores Big Pharma’s corrupt grip on health policy, where billions in vaccine profits clash with Kennedy’s drive for transparency and safety—threatening to unravel a system built on sho...